AU4599597A - Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells - Google Patents

Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells

Info

Publication number
AU4599597A
AU4599597A AU45995/97A AU4599597A AU4599597A AU 4599597 A AU4599597 A AU 4599597A AU 45995/97 A AU45995/97 A AU 45995/97A AU 4599597 A AU4599597 A AU 4599597A AU 4599597 A AU4599597 A AU 4599597A
Authority
AU
Australia
Prior art keywords
delivery
anticancer drugs
metastatic cells
hydrolyzable prodrugs
hydrolyzable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU45995/97A
Other versions
AU739028B2 (en
Inventor
Raymond Firestone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU4599597A publication Critical patent/AU4599597A/en
Application granted granted Critical
Publication of AU739028B2 publication Critical patent/AU739028B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU45995/97A 1996-09-27 1997-09-25 Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells Ceased AU739028B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4433496P 1996-09-27 1996-09-27
US60/044334 1996-09-27
PCT/US1997/017410 WO1998013059A1 (en) 1996-09-27 1997-09-25 Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells

Publications (2)

Publication Number Publication Date
AU4599597A true AU4599597A (en) 1998-04-17
AU739028B2 AU739028B2 (en) 2001-10-04

Family

ID=21931799

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45995/97A Ceased AU739028B2 (en) 1996-09-27 1997-09-25 Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells

Country Status (4)

Country Link
EP (1) EP0961619A4 (en)
AU (1) AU739028B2 (en)
CA (1) CA2264227A1 (en)
WO (1) WO1998013059A1 (en)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636889A1 (en) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastic transferrin and albumin conjugates of cytostatic compounds from the group of the anthracyclines, alkylating agents, antimetabolites and cisplatin analogues and medicaments containing them
AU1172599A (en) * 1997-11-18 1999-06-07 Chugai Seiyaku Kabushiki Kaisha Compounds with antitumor activity
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6835807B1 (en) 1998-05-22 2004-12-28 Daiichi Pharmaceuticals Co., Ltd. Drug complex and drug delivery system
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6214330B1 (en) 1998-07-13 2001-04-10 Enzon, Inc. Coumarin and related aromatic-based polymeric prodrugs
CZ20011671A3 (en) 1998-11-13 2001-10-17 Cyclacel Limited Peptide support group for transportation
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
AU768027B2 (en) * 1999-02-24 2003-11-27 Uab Research Foundation, The Taxane derivatives for targeted therapy of cancer
EP1181055A2 (en) * 1999-05-14 2002-02-27 Boehringer Ingelheim Pharmaceuticals Inc. Enzyme-activated anti-tumor prodrug compounds
US6613879B1 (en) 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
JP2003508501A (en) * 1999-09-07 2003-03-04 コンジュケム，インコーポレーテッド Pulmonary delivery for biological binding
EP1303481A1 (en) * 2000-07-26 2003-04-23 Patrick Anthony Riley Phenylethylamine derivatives and their use in the treatment of melanoma
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
BR0115109A (en) 2000-11-01 2005-10-18 Praecis Pharm Inc Therapeutic agents and methods of their use for angiogenesis modulation
US6919307B2 (en) 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
AU2002314773B2 (en) * 2001-05-09 2008-05-01 Celmed Oncology (Usa), Inc. Peptide deformylase activated prodrugs
PL372236A1 (en) * 2001-11-23 2005-07-11 Chugai Seiyaku Kabushiki Kaisha Method for identification of tumor targeting enzymes
CA2468479C (en) 2001-12-03 2010-04-27 Universitaetsklinikum Charite Der Humboldt-Universitaet Zu Berlin Technologietransferstelle Podophyllotoxins as antiproliferative agents
EP1572908A4 (en) * 2002-02-14 2008-10-22 William J Rutter Chimeric molecules for cleavage in a treated host
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
US6933302B2 (en) 2002-06-03 2005-08-23 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
ES2556641T3 (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use to treat cancer, an autoimmune disease or an infectious disease
WO2004019993A1 (en) * 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
EP1560599A1 (en) 2002-11-14 2005-08-10 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
WO2004043400A2 (en) 2002-11-14 2004-05-27 Celmed Oncology (Usa), Inc. Peptide deformylase activated prodrugs
EP2390262A1 (en) 2003-05-16 2011-11-30 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
WO2004111192A2 (en) 2003-05-29 2004-12-23 The Scripps Research Institute Targeted delivery to legumain-expressing cells
US7232805B2 (en) 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
KR20070011457A (en) 2004-04-09 2007-01-24 추가이 세이야쿠 가부시키가이샤 Novel water-soluble prodrug
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006089209A2 (en) 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
ES2708763T3 (en) 2005-07-07 2019-04-11 Seattle Genetics Inc Compounds of monomethylvaline that have modifications of the side chain of phenylalanine at the C-terminus
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
EP2183261A4 (en) 2007-07-03 2010-09-15 Childrens Hosp & Res Ct Oak Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting
PL2281006T3 (en) 2008-04-30 2018-01-31 Immunogen Inc Cross-linkers and their uses
EP2296645B1 (en) 2008-05-22 2014-11-19 Galera Therapeutics, LLC Combination antitumor therapy
WO2010005850A1 (en) 2008-07-08 2010-01-14 The J. David Gladstone Institutes Methods and compositions for modulating angiogenesis
DK2528625T3 (en) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepines and their conjugates
CN102504013B (en) * 2011-09-28 2014-03-26 李雁 Target chemical drug PADM against cancer metastasis and preparation method and use thereof
PL2773671T3 (en) 2011-11-04 2022-01-24 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
US20140364359A1 (en) * 2012-01-18 2014-12-11 Raymond A FIRESTONE Compositions and methods for treating cancer and inflammation-related dieseases and conditions
US20150335761A1 (en) * 2012-02-16 2015-11-26 Raymond Firestone Compositions and methods for contraception
US9470693B2 (en) 2012-05-18 2016-10-18 University Of North Dakota Method for quantifying proteins and isoforms thereof
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
KR102165464B1 (en) 2012-07-19 2020-10-14 레드우드 바이오사이언스 인코포레이티드 Antibody specific for cd22 and methods of use thereof
RS57694B1 (en) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
MX364327B (en) 2012-10-12 2019-04-23 Medimmune Ltd Pyrrolobenzodiazepine-anti-cd22 antibody conjugates.
HUE039329T2 (en) 2012-10-12 2018-12-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP6392763B2 (en) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ Pyrrolobenzodiazepine-antibody conjugate
CA2885340C (en) 2012-10-12 2016-11-08 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
ES2660029T3 (en) 2012-10-12 2018-03-20 Medimmune Limited Antibody-pyrrolobenzodiazepine conjugates
EP2912177A1 (en) 2012-10-23 2015-09-02 Cornell University Treatment of metastatic breast cancer
CA2890190A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
WO2014096365A1 (en) 2012-12-21 2014-06-26 Spirogen Sàrl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
ES2658888T5 (en) 2012-12-21 2021-10-19 Medimmune Ltd Pyrrolobenzodiazepines and their conjugates
PT3300745T (en) 2013-02-15 2019-11-27 Univ California Chimeric antigen receptor and methods of use thereof
JP6340019B2 (en) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6410790B2 (en) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Mitochondrial aldehyde dehydrogenase-2 modulator and method of use thereof
WO2015038426A1 (en) * 2013-09-13 2015-03-19 Asana Biosciences, Llc Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
KR102319882B1 (en) 2014-02-19 2021-11-03 아비브 테라퓨틱스, 인크. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
EP3125943A4 (en) 2014-04-04 2017-12-06 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2017006770A (en) 2014-11-25 2018-02-09 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates.
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
EP3359191A4 (en) 2015-10-05 2019-05-29 Merck Sharp & Dohme Corp. Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
WO2017062271A2 (en) 2015-10-06 2017-04-13 Merck Sharp & Dohme Corp. Antibody drug conjugate for anti-inflammatory applications
WO2017083637A1 (en) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
WO2017087723A1 (en) 2015-11-19 2017-05-26 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
EP3407916B1 (en) 2016-01-29 2023-12-20 Merck Sharp & Dohme LLC Phosphonate linkers and their use to facilitate cellular retention of compounds
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3231421A1 (en) 2016-04-11 2017-10-18 Greenaltech, S.L. Uses of a carotenoid in the treatment or prevention of stress induced conditions
CN109071634A (en) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 Antibody coupling matter and its preparation and application
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
MY198474A (en) 2016-06-01 2023-08-31 Servier Ip Uk Ltd Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
EP3571229A1 (en) 2017-01-18 2019-11-27 F1 Oncology, Inc. Chimeric antigen receptors against axl or ror2 and methods of use thereof
PT3544636T (en) 2017-02-08 2021-05-04 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
WO2018192944A1 (en) 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
KR20190141666A (en) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 Combination Therapy with Anti-AXL Antibody-Drug Conjugates
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
ES2906965T3 (en) 2017-08-18 2022-04-21 Medimmune Ltd Pyrrolobenzodiazepine conjugates
EP3505188A1 (en) 2017-12-29 2019-07-03 Invivogen Pro-cyclic dinucleotide conjugates for cytokine induction
AU2019215032A1 (en) 2018-01-31 2020-09-10 Board Of Regents Of The University Of Texas System Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
WO2019200181A1 (en) 2018-04-11 2019-10-17 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
CN108383757A (en) * 2018-04-12 2018-08-10 江苏金斯瑞生物科技有限公司 A kind of preparation method of N ε-tertbutyloxycarbonyl-N α-fluorenylmethyloxycarbonyl-N ε-methyl-lysine
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2021000644A (en) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof.
WO2020206033A1 (en) 2019-04-02 2020-10-08 Kenjockety Biotechnology, Inc. Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
EP3958908A1 (en) 2019-04-24 2022-03-02 Heidelberg Pharma Research GmbH Amatoxin antibody-drug conjugates and uses thereof
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
MX2022009355A (en) 2020-01-29 2022-09-02 Kenjockety Biotechnology Inc Anti-mdr1 antibodies and uses thereof.
AU2021284240A1 (en) 2020-06-04 2022-12-08 Kenjockety Biotechnology, Inc. Anti-ABCG2 antibodies and uses thereof
AU2021283080A1 (en) 2020-06-04 2022-12-15 Kenjockety Biotechnology, Inc. ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
WO2022043256A1 (en) 2020-08-23 2022-03-03 Cobiores Nv Synergistic combinations of anticancer drugs linked to a tetrapeptidic moiety and immunotherapeutic agents
JP2023539883A (en) 2020-09-02 2023-09-20 ケンジョッケティ バイオテクノロジー，インク． Anti-ABCC1 antibody and its use
US20240010747A1 (en) 2020-11-13 2024-01-11 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
AU2021405744A1 (en) 2020-12-22 2023-08-03 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety
CA3238353A1 (en) 2021-12-13 2023-06-22 William Robert ARATHOON Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
US20230355792A1 (en) 2022-04-07 2023-11-09 Heidelberg Pharma Research Gmbh Methods of improving the therapeutic index

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2546163B1 (en) * 1983-05-16 1987-10-09 Centre Nat Rech Scient NOVEL HYDROSOLUBLE ACYLATED DERIVATIVES OF PEPTIDES OR AMINO ACIDS, THEIR PREPARATION AND THEIR APPLICATION
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JP2001505194A (en) * 1996-11-05 2001-04-17 ブリストル―マイヤーズ・スクイブ・カンパニー Branched peptide linker

Also Published As

Publication number Publication date
EP0961619A1 (en) 1999-12-08
EP0961619A4 (en) 2001-09-26
CA2264227A1 (en) 1998-04-02
AU739028B2 (en) 2001-10-04
WO1998013059A1 (en) 1998-04-02

Similar Documents

Publication Publication Date Title
AU4599597A (en) Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
AU8399298A (en) Process for preparing fast dispersing solid oral dosage form
AU3287699A (en) Ultrasound-mediated drug delivery
AU6141199A (en) Multiplex drug delivery system suitable for oral administration
AUPO721997A0 (en) Anticancer compounds
AU6011496A (en) Improved pharmaceutical compositions for gene therapy
AU4400797A (en) Colon selective drug delivery composition
AU8699598A (en) Multi-lumen cannula
AU2638297A (en) Oral pharmaceutical preparation containing ibandronat
AU2127697A (en) Method of preparing polynucleotide-carrier complexes for delivery to cells
AU4892897A (en) Phospholipid drug derivatives
AU7595498A (en) Medicament dispensing cell
AU2682395A (en) Crude Drug-Containing Feed
AU3904099A (en) Drug delivery module
AU3290397A (en) Gastric-retentive oral controlled drug delivery system with enhanced retention properties
AU3999699A (en) Targeted liposomal drug delivery system
AU1694400A (en) Transdermal delivery system containing buprenorphine
AU5934598A (en) Manufacture of ascorbyl monophosphates
AU2337897A (en) Uniform drug delivery therapy
AU1689999A (en) Medicinal composition for percutaneous administration
AU2508597A (en) Drug for the treatment of tumours
AU3855197A (en) Use of amines to produce drugs for preventing tumour cell proliferation
AU2351995A (en) Medicinal composition as a remedy for non-small cell lung cancer
AU9740898A (en) Medicaments containing acyclovir
AU2559995A (en) Transdermal delivery of anti-epileptic drugs

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)